Abbott Launches EnSite Precision Cardiac Mapping System
January 16, 2017—Abbott Vascular announced the United States launch and the first commercial uses of the EnSite Precision cardiac mapping system and Advisor FL circular mapping catheter, with Sensor Enabled technology to map cardiac arrhythmias during ablation treatments. The system is designed to provide automation, flexibility, and precision for the treatment of patients experiencing arrhythmias from multiple origins in the heart. Abbott Vascular acquired the devices as part of the acquisition of St. Jude Medical, Inc., which closed on January 4.
The first commercial use of the system after US Food and Drug Administration clearance occurred during ablation procedures conducted by electrophysiologist John Day, MD, at the Intermountain Heart Institute in Salt Lake City, Utah. Additional procedures supported by the new EnSite Precision cardiac mapping system have occurred in 12 states nationwide, supporting ablation procedures to treat complex arrhythmias.
In the company's announcement, Dr. Day commented, "The new EnSite Precision cardiac mapping system allows better three-dimensional images of the arrhythmias in the heart, which improve the accuracy of what we see during the procedure so we can more precisely treat the patient. We were excited to perform the inaugural case in the United States, and we continue to utilize the system daily to provide the best patient care possible."